




 Institute of Psychiatry, Hospital das Clínicas da Faculdade de Medicina da 
Universidade de São Paulo - São Paulo/SP, Brazil.
II
 Institute of Mathematics and Statistics, Universidade de São Paulo - São 
Paulo/SP, Brazil.
III
 Preventive Medicine Department, Federal University of Rio de Janeiro - 
Rio de Janeiro/RJ, Brazil.
Email: victor.ime@gmail.com
Tel: 55 11 3069-6972
Received for publication on January 26, 2009
Accepted for publication on March 10, 2009
SEquENtIAL ALLoCAtIoN to bALANCE 
progNoStIC fACtorS IN A pSyChIAtrIC 
CLINICAL trIAL
Victor Fossaluza,I,II Juliana Belo Diniz,I Basilio de Bragança Pereira,III 
Eurípedes Constantino Miguel,I Carlos Alberto de Bragança PereiraI,II  
 
doi: 10.1590/S1807-59322009000600005
Fossaluza V, Diniz JB, Pereira BB, Miguel EC, Pereira CAB. Sequential allocation to balance prognostic factors in a psychiatric 
clinical trial. Clinics. 2009;64(6):511-8.
OBJECTIVE: This paper aims to describe and discuss a minimization procedure specifically designed for a clinical trial that 
evaluates treatment efficacy for OCD patients. 
METHOD: Aitchison’s compositional distance was used to calculate vectors for each possibility of allocation in a covariate adap-
tive method. Two different procedures were designed to allocate patients in small blocks or sequentially one-by-one. 
RESULTS: We present partial results of this allocation procedure as well as simulated data. In the clinical trial for which this 
procedure was developed, successful balancing between treatment arms was achieved. Separately, in an exploratory analysis, we 
found that if the arrival order of patients was altered, most patients were allocated to a different treatment arm than their original 
assignment. 
CONCLUSION: Our results show that the random arrival order of patients determine different assignments and therefore maintains 
the unpredictability of the allocation method. We conclude that our proposed procedure allows for the use of a large number of 
prognostic factors in a given allocation decision. Our method seems adequate for the design of the psychiatric trials used as models. 
Trial registrations are available at clinicaltrials.gov NCT00466609 and NCT00680602.
KEYWORDS: Clinical research; Randomization; Aitchison’s compositional distance.
INTRODUCTION
For certain specific psychiatric disorders, large trials 
are fairly rare. Obsessive-compulsive disorder (OCD), for 
instance, has only been studied in small trials. First-line 
treatments such as clomipramine and selective serotonin 
reuptake inhibitors are typically studied in trials with no 
more than two hundred patients.1 For second-line treatments 
such as pharmacological augmentation strategies, the 
situation is worse, albeit understandably so.2,3 To our 
knowledge, no trials have investigated these strategies 
using more than one hundred patients. Indeed, most such 
studies have presented final sample sizes of no more than 
15 patients per arm.3 This is in stark contrast to studies of 
common clinical diseases such as hypertension and diabetes. 
Therefore, certain specific aspects of trial design need to be 
taken into consideration when implementing clinical trials 
involving psychiatric patients, especially those with OCD.
In small trials, such as those typically used to study 
psychiatric disorders, an imbalance in prognostic factors 
between treatment arms can affect the interpretation of 
the results. One of the first methods created to address this 
problem was stratified allocation of individuals.4 The use of 
this method also reduces the need to adjust statistical data 
analyses for covariates that serve as prognostic factors. The 
limitation of stratified allocation is that it can only be applied 
when a small number of covariates are involved. Otherwise, 
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the sample has to be divided into a large number of strata 
with only a very few patients in each.5 In order to overcome 
this limitation, it is necessary to devise alternative methods 
of minimizing imbalance among treatment arms.
Pocock and Simon6 devised a general procedure for 
treatment assignment that minimizes imbalance among 
individual prognostic factors. Independently, Taves7 also 
developed a minimization procedure that will not be 
discussed in this article, as it is encompassed by the Pocock 
and Simon method.
Since 1975, various other authors have developed 
procedures to minimize the risk of imbalance between 
arms, as reviewed elsewhere.8,9 Each method has specific 
limitations and complexities. For example, the optimal 
allocation technique allows the use of continuous variables 
in their non-categorical format as covariates.10 However, 
the complexity and associated difficulty has limited its 
practical implementation. No allocation procedure is ideal 
- accordingly, novel methods are still required in specific 
situations.
In response to the need for specific minimization 
procedures in clinical trials involving individuals with 
OCD, we developed an allocation method that uses the 
Aitchison distance,11-13 which is a measure for compositional 
data (data that contains quantitative descriptions of the 
parts of some whole). The Aitchison distance was chosen 
because all prognostic factors used are better classified as 
categorical data with relative frequencies that can be taken 
as compositional data in nature. 
We present allocation results for a partial sample 
collected during the first year of the study for which this 
procedure was developed, as well as results for simulated 
samples that feature variable patient’s order of inclusion. 
METHOD
The trials reported in this manuscript received prior 
approval from our local ethics committee. 
Allocation
For clarity, let us first consider the simplest design. 
Consider a clinical trial in which patients are enrolled 
sequentially, according to the order in which they commence 
treatment at the clinic. Each patient is to be assigned to 
one, and only one, of two alternative treatments. Imagine 
that a new patient arrives after the study already included a 
considerable number of patients in each of the two arms: n1 
and n2. In addition, consider that age, denoted a, is a factor 
for which we think adjustment should be made. Possible 
ages are divided into three different categories: a1 if a < 
30; a2 if 30 < a < 45; and a3 if a > 45. Consider now the 
following notation:
1. Represent the sample absolute frequencies of n1 and n2, 
respectively, as (n11,n12,n13) and (n21,n22,n23), i.e., for i = 1 
or 2 and j = 1, 2 or 3, nij is the number of patients of age 
group aj in arm i. 
2.  Represent the compositional vectors (relative fre-
quency vectors), respectively, as A1 = (a11,a12,a13) and 
A2 = (a21,a22,a23). Thus, aij = nij /ni represents the relative 
frequency of patients in age group aj in arm i given the 
proportion of age group aj in arm i. 
The allocation of a new incoming patient consists of the 
following steps: 
i. Consider including the new patient in the first arm, in 
which case we represent the new composition vector by 
(A1)*, and we calculate the distance between (A1)* and 
A2 by evaluating d1 = Δ [(A1)*;A2]. 
ii. Consider including the new patient in the second arm, in 
which case we represent the new compositional vector by 
(A2)*, and compute the distance d2 = Δ [A1;(A2)*].
iii. Compare the values of d1 and d2. If d1 < d2, we allocate 
the new patient to n1; if d1 > d2, we allocate the patient to 
n2; and if d1 = d2, the patient may be allocated to either 
arm (at random). 
Note that we make our decision based on the values of 
the distances between the compositional vectors. We use 
the term “compositional vectors” to designate vectors for 
which the sum of their components is fixed and known. 
In our case, with relative frequencies, the values of the 
components are numbers in the interval [0;1], and the sum 
of these components is one. Aitchison11,12 argued that, for 
compositional data, the correct distance measure is not the 
usual standard Euclidian measure but is instead as described 
below.
In general, consider factor a having k (>1) possible 
alternatives, i.e., Ai = (ai1,ai2,…,aik) is the relative frequency 
vector of arm i (=1,2). For category j, consider the natural 
logarithm of the between-arm relative frequency ratio, 
rj = (a1j ÷ a2j), denoted by ln(rj), and the mean of these 
logarithms, denoted by L: 
ln(rj) = ln(a1j) - ln(a2j) and L = {ln(r1) + ln(r2) + … 
+ ln(rk)} ÷ k
The Aitchison distance measure between the two 
compositional vectors A1 and A2 is defined as follows:
To demonstrate the allocation procedure, let us consider 
the case of the three age categories a1, a2, and a3, as before. 
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Suppose that, in one stage of the process, we encountered 
the following vectors of absolute frequencies: n1 = (3;7;5) 
and n2 = (5;6;6). A new patient enrolls and falls under age 
category a2. Table 1 presents the vectors used to calculate the 
required distances.
The following three expressions represent the intragroup 
distances, (not) including the new patient:
A) Before the arrival of the new patient, Δ[A1;A2] = 0.4702
B) With the new patient in n1, Δ[(A1)*;A2] = 0.5676
C) With the new patient in n2, Δ[A1;(A2)*] = 0.3661
The figures above indicate that a new patient in age 
group a2 should best be allocated to n2. This conclusion 
might appear obvious to the decision-maker, as it is desirable 
to increase the frequency of a2 in n2. Note that this choice 
increases the n2 sample size. We are also interested to control 
the arm sample sizes. Let us transform the sample size (s) 
into a compositional factor. Let us consider the vectors S1 = 
(s1;s2) ÷ s and S2 = (s2;s1) ÷ s as the relative frequencies of 
n1 and n2, respectively. In our example we would have the 
following: 
S1 = (15;17) ÷ 32 = (.47;.53) , S2 = (.53;.47) , (S1)* = 
(.48;.52) and (S2)* = (.55;.45)
Here the * indicates that the new patient entered a 
specific arm. The new distance values are Δ[S1;S2] = 
0.1770, Δ[(S1)*;S2] = 0.1314, and Δ[S1;(S2)*] = 0.2174. 
Clearly, the best allocation would be to the first arm, which 
features a smaller sample size. Bear in mind that, given 
the age categories above, our best choice would have been 
to allocate the new patient to the second arm. However, 
considering the sample size factor, the first arm is the more 
appropriate allocation for the new patient. If the decision-
maker feels that age is more important than sample size, a 
larger weight could be assigned to age than to sample size. 
For example, consider our decision to use a weight of 2 for 
age and a weight of 1 for sample size. The weights reflect 
the importance of covariates and should be prospectively 
made in agreement with the investigators. We may use the 
weighted average of the distances to guide this decision. The 
results for our example are as follows: 
i. new patient in n1 produces D1 = {2Δ[(A1)*;A2] + 
Δ[(S1)*;S2]} ÷ 3 = 0.4222
ii. new patient in n2 produces D2 = {2Δ[A1;(A2)*] + 
Δ[S1;(S2)*]} ÷ 3 = 0.3165
The overall distance using the two factors indicates 
that the new patient should be allocated to n2 in order to 
bring the arms closer in terms of age and sample size. It 
may also be possible to assign equal weights to the two 
factors. Regarding the constructed factor for sample size, to 
appropriately compare factors, we need to adopt the same 
range for all factor distance measures. Hence, the definitions 
of S1 and S2 seem quite adequate. 
The examples discussed below are more specific and 
demonstrate several interesting particularities. The first, 
related to phase one of the trial described, deals with two 
arms, four prognostic factors, and a simultaneous allocation 
of three patients each time. The second example, related to 
phase two, deals with seven prognostic factors and allocation 
of patients one at a time into the three groups. 
Two-phase clinical trial
A study group specializing in OCD wished to conduct a 
clinical trial consisting of two phases. The objective of phase 
one was to compare patient responses to pharmacological 
and psychotherapeutic treatments. They expected that 
360 OCD patients would be enrolled in phase one over a 
3-year period. However, for logistical reasons, they did 
not anticipate that the numbers of patients allocated to the 
individual treatment arms would be similar in phase one. 
They anticipated that the pharmacological arm may receive 
more patients than the psychotherapeutic arm at certain 
times, and vice-versa at other times. These variations are 
required because, for practical reasons, each therapeutic 
arm must accommodate a different number of patients at 
different times in the study. As the psychotherapeutic arm 
involves group psychotherapy, when groups are first created, 
a rapid influx of patients is necessary, but when groups are 
well-established, the speed of inclusion should diminish as 
only two groups can be conducted simultaneously. 
From previous experience, we expected that 60% of 
the patients treated in either of the two arms of phase one 
would report less than adequate symptom improvement. 
Patients who participated in the pharmacological arm 
(n1) and did not respond to treatment would be invited to 
participate in phase two. Patients who were non-responders 
in the psychotherapeutic arm (n2) of phase one would be 
invited to participate in the pharmacological arm (n1), 
and, if treatment resistance were to persist in n1, they 
would also be invited to participate in phase two. Phase 
Table 1 - Vectors of relative frequencies
Aging A1 A2 A1* A2*
a1 0.2000 0.2941 0.1875 0.2778
a2 0.4667 0.3529 0.5000 0.3889
a3 0.3333 0.3529 0.3125 0.3333
Sum 1 1 1 1
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two consists of three arms, the objective being to compare 
three different pharmacological augmentation strategies. In 
phase two, unlike in phase one, it is expected that a similar 
number of patients will be allocated to each of the three 
arms. Considering expected response rates, drop-out rates, 
and frequency of refusals to participate in a study using a 
placebo, it is likely that 30 to 40 patients will be included in 
each arm. This sample size seems adequate according to the 
investigator’s hypothesis. The entire clinical trial design is 
illustrated in Figure 1. 
The allocation strategies for the two phases of the trial 
are different. To accommodate the logistical characteristics of 
phase one (that require a different pace of patient enrollment 
for each arm at different study time points), the researcher 
will receive groups of 3 patients to be allocated into the two 
groups. On some occasions, it might be necessary to allocate 
2 patients to n1 and 1 to n2. On other, well-defined occasions, 
the situation is reversed, and n1 will receive 1 patient while 
the other 2 patients will be allocated to n2. 
Prognostic factors to be balanced across arms
When the allocation program was developed for phase 
one, a smaller number of variables was chosen, as we 
did not know how many covariates this new procedure 
could accommodate without compromising its efficiency 
in minimizing arm imbalance. After the initial results of 
allocation were analyzed for phase one, it became clear 
that the procedure could accommodate a greater number 
of covariates. Therefore, the program for phase two was 
designed with a greater number of hypothesized prognostic 
factors that could also have been covariates in phase one. The 
factors used to establish the allocating strategy were chosen 
based on previous studies. Although the appropriateness 
of the factors used might be obvious, discussion of these 
choices is outside the scope of this paper. Our sole intention 
is to present the allocation strategy used in the study 
described. The factors and their categories were as follows: 
1. Current age (age) was categorized into three classes: 
under 30 years of age (a0); between 31 and 45 (a1); and 
over 45 (a2). 
2. OCD symptom severity (OCD), as measured using the 
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), was 
categorized under one of eight classes based on ordered 
scores for each of the two symptom types (obsession and 
compulsion): ≤ 8 = low (L); 8-15 = moderate (M); and > 
15 = high (H). Therefore, the eight possible classes were 
as follows: (L;L), (L;M), (L;H), (M;L), (M;M), (M;H), 
(H;L), (H;M), and (H;H). The first and second notations 
are based on the scores for obsession and compulsion, 
respectively. Clearly, (L;L) is not considered, as it would 
indicate no OCD symptoms, and we had no patients in 
this class.
3. Treatment history (his) was divided into three categories 
in each phase. In phase one, h0 indicates no previous ap-
propriate treatment, h1 indicates one previous course of 
appropriate treatment without response, and h2 indicates 
two or more previous courses of appropriate treatment 
without response. In phase two, h0 indicates no Y-BOCS 
score reduction or Y-BOCS score increase after n1 in 
phase one, h1 indicates a 1-20% reduction in Y-BOCS 
score after n1 in phase one, and h2 indicates a 20-35% 
reduction in Y-BOCS score after n1 in phase one.
4. Level of education (sch) was divided into four catego-
ries: sc0 indicates no schooling, sc1 indicates ≤ 8 years of 
schooling, sc2 indicates 9-12 years of schooling, and sc3 
indicates higher education (undergraduate or graduate 
work).
5. Marital status (mar) was categorized as si0 (married, 
divorced or widowed) or si1 (single, never married). 
6. Genders (gen) are indicated by m for male and f for fe-
male.
7. Sample sizes (sam) are denoted as s1, s2, s3, and s = s1 + 
s2 + s3 represents the total sample size. Note that there are 
three arms only in phase two. The compositional vector 
of sample size in arm i (i = 1,2,3) is the vector (pi;1-pi) 
where pi = si ÷ s.
For each of these factors, the distance between arms can 
be computed. The distance values for the seven variables 
listed above are given by the following symbols: Δ
age, 
ΔOCD, Δhis, Δsch, Δmar, Δgen, and Δsam. The global distances for 
phases one and two are, respectively, Δ1 and Δ2, defined as 
follows:
Δ1 = (2Δage + 3ΔOCD + 3Δhis + Δgen) ÷ 9
Δ2 = (2Δage + 4ΔOCD + 5Δhis + 2Δsch + 3Δmar + Δgen + 4Δsam) ÷ 21
As there are three arms in phase two, there are also three 
vectors. Hence the global distance for phase two should be 
the average of the three values of Δ2, i.e., the distance for 
phase two should be as follows: 
Δ2= {Δ2(n1;n2) + Δ2(n1;n3) + Δ2(n2;n3)} ÷ 3
Phase one allocation strategy
Based on previous studies, factors measurable before 
treatment initiation may influence the treatment response. 
Therefore, it is desirable that certain prognostic factors 
be distributed as homogeneously as possible between the 
two arms. We assume that previous treatment response 
(assessed through patient interviews) and severity of the 
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disorder (assessed using a specific scale) at the time of 
inclusion in the study are the most important prognostic 
factors for clinical response. In addition, although of lesser 
importance to treatment response, gender and age should 
also be homogeneously distributed between arms. For 
logistical reasons, it was not possible to enroll the same 
number of patients in each phase one treatment arm. The 
healthcare professionals who administer the treatments can 
assist more patients in the pharmacological arm than in the 
psychotherapeutic arm. Over the course of the study, there 
are times at which the pace of patient enrollment into the 
psychotherapeutic arm is, of necessity, more rapid than 
that of patient enrollment into the pharmacological arm. 
We expect that the pharmacological arm will account for 
a higher percentage of the final sample. Due to the time 
needed to perform the clinical evaluations, there is a two-
week gap between inclusion and allocation. Consequently, 
it is possible to allocate patients simultaneously in groups 
of three, one to one arm and the remaining two to the other 
arm (the arm that receives two patients at certain time points 
will only receive one at other time points). This simultaneous 
inclusion of patients guarantees that provider blinding is not 
compromised by allocation in small blocks. 
The choice of prognostic factors to be balanced between 
arms is based on reports in the literature that suggest 
that these prognostic factors may influence the results 
considerably. In addition, having information about these 
factors at the time of the initial evaluation is feasible and 
provides useful clues for balancing between intervention 
groups. As previous treatment response and initial severity 
are known to be associated with treatment response in 
clinical trials evaluating OCD patients,14-18 they were 
included as prognostic factors in order to balance the arms. 
Phase two allocation strategy 
Patients entering phase two were those that failed to 
completely respond to the treatment in n1 of phase one 
(regardless of treatment history). The investigators assumed 
that treatment response and current severity were highly 
predictive of phase two treatment response, and that these 
patients should therefore be distributed homogeneously 
among the three groups. In addition, it is understood from 
previous studies that level of education and marital status 
are significantly associated with poor treatment response and 
should be included in the phase two strategy model. Gender 
and current age should also be distributed homogeneously 
among the three arms. Another important factor is sample size, 
which should be as similar as possible among the three arms. 
For each patient in phase two, the allocation to one of 
the three arms needs to be determined during the evaluation 
conducted at week 12 of treatment. The strategy at this point 
involves a sequential, one-by-one allocation of patients who 
had participated in phase one. Here, in addition to having 
more than two factors to consider in our attempts to balance 
the arms, we are dealing with three arms. Bear in mind that 
though the distance measures are defined for two vectors in 
order to facilitate decisions regarding patient allocation, we 
consider the average of the three distances between pairs to 
represent the overall distance of the three arms. The proposed 
solutions for the two phases are described below. 
RESULTS
Partial results for phase one 
To perform stratified allocation of patients, a Microsoft 
Excel macro was created. This macro divided patients into 
homogenous intervention subgroups consistent with the 
factors chosen by investigators. To avoid empty categories 
in the allocation process, for a factor with k (>1) categories, 
we added to each category the fraction 1/k. Therefore, no 
category had a frequency of 0 at the time of Δ distance 
calculation. 
The partition that provides the best degree of 
homogeneity between groups is defined as the division 
that minimized the difference between factor vectors of 
categorized relative frequencies. To calculate this measure, 
the Aitchison distance between two vectors was used, as 
previously discussed. This distance was chosen based on 
the assumption that it preserves the sub-compositional 
coherence of the simplex space. After the values of Δ1 were 
calculated for each possible allocation, the allocation that 
resulted in the least intragroup distance was chosen as the 
optimal allocation. 
At the time of writing, 152 individuals had been allocated 
to n1 and 107 had been allocated to n2. The partial allocation 
results are shown in Table 2. The results of the reverse order 
allocation of patients appear in parentheses.
Simulated results for phase two
The phase two allocation system has the same objectives 
as that of phase one, namely to bring the arms as close 
together as possible in terms of the relevant prognostic 
factors. However, in phase two, the allocation logistics are 
different than those in phase one. We now have three arms, 
and the patients are allocated sequentially one-by-one. In 
addition, the balancing factors in this phase are different 
from those considered in phase one. As well as now 
accounting for level of education, marital status, and sample 
size, the previous treatment history factor, unlike in phase 
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Table 2 - Partial (reverse order) allocation of 259 patients in phase one
Prognostic factor Compositional
category
Arm 1 frequencies Arm 2 frequencies
Absolute Relative Absolute Relative
Current age a0 71 (71) 0.467 49 (49) 0.458
a1 53 (52) 0.349 38 (38) 0.355
a2 28 (29) 0.184 20 (20) 0.187
OCD symptom severity (L;M) 2 (2) 0.013  1 (1) 0.009
(M;L) 2 (2) 0.013  1 (1) 0.009
(L;H) 3 (3) 0.020  2 (2) 0.019
(H;L) 3 (2) 0.020  0 (1) 0.000
(M;M) 59 (59) 0.388 42 (42) 0.393
(M;H) 19 (18) 0.125 12 (13) 0.112
(H;M) 17 (16) 0.112 11 (12) 0.103
(H;H) 47 (50) 0.309 38 (35) 0.355
Treatment history h0 78 (82) 0.513 61 (57) 0.570
h1 49 (44) 0.322 30 (35) 0.280
h2 25 (26) 0.165 16 (15) 0.150
Gender m 63 (63) 0.414 44 (44) 0.411
f 89 (89) 0.586 63 (63) 0.589
Sample size Arm size 152 0.587 107 0.413
Complement 107 0.413 152 0.587
Table 3 - Sequential (reverse order) allocation of 90 patients in phase two: patients from phase one
Prognostic factor Compositional
Category
Arm 1 frequencies Arm 2 frequencies Arm 3 frequencies
Absolute Relative Absolute Relative Absolute Relative
Current age a0 13 (14) 0.433 13 (12) 0.433 14 (14) 0.467
a1 13 (12) 0.433 12 (12) 0.400 11 (12) 0.367
a2 4 (4) 0.133 5 (5) 0.167 5 (5) 0.167
OCD symptom severity (L;M) 0 (1) 0.000 0 (0) 0.000 1 (0) 0.033
(M;L) 0 (0) 0.000 0 (0) 0.000 0 (0) 0.000
(L;H) 0 (0) 0.000 0 (0) 0.000 0 (0) 0.000
(H;L) 1 (1) 0.033 0 (1) 0.000 1 (0) 0.033
(M;M) 12 (11) 0.400 14 (12) 0.467 10 (13) 0.333
(M;H) 2 (2) 0.067 2 (2) 0.067 3 (3) 0.100
(H;M) 4 (3) 0.133 3 (4) 0.100 4 (4) 0.133
(H;H) 11 (12) 0.367 11 (10) 0.367 11 (11) 0.367
Treatment history h0 15 (15) 0.500 15 (15) 0.500 15 (15) 0.500
h1 9 (10) 0.300 10 (9) 0.333 10 (10) 0.333
h2 6 (5) 0.200 5 (5) 0.167 5 (6) 0.167
Level of education sc0 14 (15) 0.467 15 (14) 0.500 15 (15) 0.500
sc1 0 (0) 0.000 0 (0) 0.000 0 (0) 0.000
sc2 0 (0) 0.000 0 (0) 0.000 0 (0) 0.000
sc3 16 (15) 0.533 15 (15) 0.500 15 (16) 0.500
Marital status si0 16 (15) 0.533 15 (15) 0.500 15 (16) 0.500
si1 14 (15) 0.467 15 (14) 0.500 15 (15) 0.500
Gender m 13 (13) 0.433 13 (12) 0.433 13 (14) 0.433
f 17 (17) 0.567 17 (17) 0.567 17 (17) 0.567
Sample size Arm size 30 (30) 0.333 30 (29) 0.333 30 (31) 0.333
Complement 60 (60) 0.667 60 (61) 0.667 60 (59) 0.667
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one, is based on the relative reduction, during phase one, in 
the Y-BOCS score. Patients who present a > 35% reduction 
in Y-BOCS score are not included in this phase. In order to 
consider sample size as a factor, the proportion of patients in 
each group will also be included in the distance calculation. 
Table 3 presents the allocation results for 90 patients selected 
from those in n1 of phase one. 
DISCUSSION
The objective of using this strategy of random allocation 
of patients in different treatment arms is to avoid intentional 
bias in group allocation. However, treatment group 
imbalance for prognostic factors can still occur.9 These 
unfortunate consequences of randomization can only be 
prevented by using techniques that produce an intentional 
optimal allocation of patients to each treatment arm. 
Another interesting point is the choice of the Aitchison 
distance to treat compositional data. To illustrate the 
difference between the Aitchison distance and the standard 
Euclidian distance, we calculate the two distances for the 
pairs (A1;A2) and (B1;B2) of relative frequency vectors defined 
below: 
A1 = (0.1;0.2;0.7) , A2 = (0.2;0.1;0.7) , B1 = (0.2;0.4;0.4), and 
B2 = (0.4;0.2;0.4)
The standard Euclidian measure would produce D[A1;A2] 
= 0.1414 and D[B1;B2] = 0.2828. Note that the Aitchison 
distance will produce the same value for both pairs: Δ[A1;A2] 
= Δ[B1;B2] = 0.9803, as expected for an adequate distance. 
Note that, for any category j (= 1, 2, 3), the ratio between 
frequencies is the same for the two pairs: 
a1j ÷ a2j = b1j ÷ b2j
We also note that problems occur if a frequency of 0 is 
listed for a particular class. To address this, we recommend 
that prior correction be used, commencing the allocation 
process at a small real number for each category that should 
be added to the observed absolute frequency. As an analogy 
to Bayesian categorical data analysis, we adopt an equally 
constant for each category, as with the standard strategy. Our 
recommendation is to add 1/k to the absolute frequencies for 
each category, thereby avoiding the occurrence of a relative 
frequency of 0 in any category. 
The “random” aspect of treatment arm allocation is 
preserved due to the random sequence in which patients 
arrive for inclusion in clinical trials. The most important 
property of the allocation strategy defined here is that we 
can verify post hoc adherence to the desired strategy. The use 
of a purely randomized strategy cannot be proven after the 
trial has been concluded. To verify that the order in which 
the patients entered the experiment was indeed random, we 
considered the reverse order of the first 259 patients (phase 
one) and 90 patients (phase two). In Tables 2 and 3, it can 
be seen how close the results from the reverse order are to 
those obtained for the original order. An interesting fact is 
illustrated in Tables 4 and 5. We can see that more than half 
of the patients would change arms by reversing the order in 
which they enter into a phase. In phase one, 130 of the 259 
patients would have changed arms if the reverse order had 
been considered. For phase two, under the reverse order, 48 
of the 90 patients would have changed arms.
This article describes a method of computer-based 
intentional allocation that has the advantage of being 
flexible, effective, and feasible for the allocation of each 
consecutive patient, or groups of three patients, in terms 
of multiple covariates. Future studies are still needed to 
evaluate the effectiveness of this procedure when a large 
number of covariates are included. The procedure presented 
here is reliable for the inclusion of up to six compositional 
covariates with twenty-one possible alternative results. 
When using this procedure, researchers could include 
any allocation strategy variables suspected of influencing 
treatment response. 
One limitation of the proposed procedure is the need to 
know the value of each prognostic factor, for each patient 
entering the study, prior to allocation. Consequently, values 
of prognostic factors that can only be obtained through 
long-term evaluation cannot be included in the model. 
Another issue is the weights given to the allocation factors. 
For the trial in question, the second author (the psychiatrist 
responsible for conducting the trial) based the choice of 
variable weights on the evidence levels of the prognostic 
Table 4 - Phase one patient allocation
 Reverse order Sample
Original order arm 1 arm 2 Size
arm 1 87 65 152
arm 2 65 42 107
Sample size 152 107 259
Table 5 - Phase two patient allocation
 Reverse order Sample
Original order arm 1 arm 2 arm 3 Size
arm 1 15 9 6 30
arm 2 10 11 9 30
arm 3 5 9 16 30
Sample size 30 29 31 90
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factors that influence treatment response. Although this 
was an arbitrary decision, it does not favor any allocation 
tendency that might result in arm imbalance. Thus, there is 
no imbalance that might favor a particular result in terms of 
treatment response. 
CONCLUSION
In conclusion, the procedure described here can be easily 
adapted to different study designs. The results of the trial, 
used as illustration, show that the methodology was reliable 
for the sample tested. There are, however, some reliability 
issues that require further investigation, such as the inclusion 
of cases presenting a large number of factors or factors that 
feature a large number of possible alternative categories. 
Nevertheless, we believe that this paper presents a procedure 
that will be useful in avoiding imbalance among treatment 
arms when patient allocation is performed sequentially. 
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